Phase 2 N=53 Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy
Ulcerative Colitis
Primary: Detected Intraepithelial Neoplasia — 0.2 Number of detected IN
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=269 Complete Histologic Resection of Adenomatous Polyps?
Adenomatous Polyps
Primary: Percent of Incompletely Resected Adenomatous Polyps — 10.1 percentage of incomplete resection
N/A N=14,263 Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study
Colorectal Cancer · Advanced Adenocarcinoma · Serrated Polyp
Primary: ColoSense Sensitivity for Colorectal Cancer (CRC) — 25; 2 Participants
Phase 2 N=6 A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib
HER2 Amplified Breast Cancer
Primary: Changes in Colon Pathology — 2; 2 participants
Phase 4 N=360 Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage
Spinal Cord Injury
Primary: Quality of Bowel Preparation — 3.4; 2.5; 3.6; 7.4 units on a scale
N/A N=99 Laparoscopic Complete Mesocolic Excision on Colon Cancer
Operation Finding · Complications · Pathology
Primary: Histopathological Outcomes Obtained Through the Surgeries — 20.3; 19.2 nodes
N/A N=265 Colorectal Cancer: Screening vs. Non-Screening
Colorectal Cancer · Screening
Primary: Colorectal Cancer Stage (pTNM) — 46; 85 Participants
N/A N=804 Narrow-Band Imaging Versus Standard White Light for the Detection of Serrated Lesions in the Proximal Colon
Colon Cancer
Primary: Total Number of Serrated Lesions Proximal to the Sigmoid Colon — 204; 158; 95; 59 Serrated Lesions
Phase 2 N=16 Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)
Colon Cancer · Rectal Cancer
Primary: Efficacy of Lymphoseek for Detection of Sentinel Nodes — 16 Participants
Phase 2 N=40 Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib
Colorectal Adenoma · Colorectal Carcinoma
Primary: Number of Subjects Witha Change (IMPROVEMENT) in Colo-rectal Adenocarcinoma as Measured by Cyclooxygenase-2 Activity After 7 Days of Celecoxib — 2.0; 2.0 Participant
N/A N=2,600 The National CT Colonography Trial
Colorectal Cancer
Primary: Number of Participants With Advanced Adenomas (>=10mm) as Determined by Colonoscopy (Per Patient) — 109; 2422 Participants
N/A N=1,855 The Colorectal Breath Analysis (COBRA) Study
Colorectal Cancer · Colorectal Polyps · Colorectal Adenocarcinoma
Primary: Determine the Diagnostic Accuracy of the Proposed Breath Test for Detection of Colorectal Cancer in All Patients — 79; 86 percentage of true cases
N/A N=281 Study of Flat Polyp Detection Using New Narrow Band Imaging (NBI) Compared to White Light Colonoscopy - The FIND FLAT Colonoscopy Study
Colorectal Neoplasms · Colonic Polyps · Colorectal Cancer
Primary: Number of Participants With Nonpolypoid (Flat and Depressed) Colorectal Neoplasm — 33; 43 Participants
N/A N=100 Cap-fitted Colonoscopy: a Randomized, Tandem Colonoscopy Study of Adenoma Miss Rates
Polyps
Primary: Number of Adenomas — 83; 89; 28; 44 First Colonoscopy number of adenomas
Phase 2 N=64 Neoadjuvant Therapy for Locally Advanced Colon Cancer
Colon Cancer · Neoadjuvant Therapy
Primary: Tumor Regression Rate of MSS/pMMR Patients — 7 Participants
N/A N=384 Post-resection Treatment of Large Colon Polyps
Recurrence
Primary: Recurrence — 10; 5; 24 Polyps
Phase 2 N=20 Cellular Immune Augmentation in Colon and Rectal Cancer
Colon Cancer · Rectal Cancer
Primary: Participants Exhibiting Immune Response — 11 Participants
Phase 3 N=204 Adjuvant HIPEC in High Risk Colon Cancer
Colorectal Neoplasms · Peritoneal Neoplasms
Primary: Peritoneal Recurrence Free Survival at 18 Months — 79; 80 participants
N/A N=1,111 Helping Patients and Providers Make Better Decisions About Colorectal Cancer Screening
Cancer Screening Tests
Primary: Number of Participants Who Completed Colorectal Cancer Screening — 110; 95; 113; 113 Participants
N/A N=928 Safety of Endoscopic Resection of Large Colorectal Polyps: A Randomized Trial.
Colon Polyps
Primary: Number of Participants With Delayed Bleeding Complications — 16; 33 Participants
Phase 2 N=30 Lymphatic Mapping for Sentinel Node Identification and Analysis
Colorectal Cancer
Primary: Subjects in Which the SLN(s) Are Identified — 27 Participants
N/A N=40 Hybrid APC Assisted EMR for Large Colon Polyps
Colon Polyp · Colon Adenoma · Colon Cancer
Primary: Percentage of Participants Having Complete Resection — 40 Participants
N/A N=100 Detection of Colonic Polyps Via a Large Scale Artificial Intelligence (AI) System
Colonic Polyp
Primary: Number of Additional Polyps Detected by the DEEP System in Real Time Colonoscopy — 0.89 Added polyps detected per colonoscopy
Phase 3 N=332 PillCam™ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon
Colonic Diseases
Primary: Number of Participants With Successful Capsule Endoscopies or Standard Colonoscopies — 322; 326 participants
N/A N=11,016 Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Colorectal Neoplasms · Digestive System Diseases · Colonic Diseases
Primary: Sensitivity and Specificity of the Exact CRC Screening Test With Comparison to Colonoscopy, Both With Respect to Cancer. — 92.3; 73.8; 93.3; 73.3 percent
N/A N=35 Anthocyanin Extract and Phospholipid Curcumin in Colorectal Adenoma
Colorectal Adenoma · Risk Reduction
Primary: Change in Beta Catenin Expression — 100; 100; 100; 100 percentage of positive cells
N/A N=211 The Use of Narrow Band Imaging in Screening Colonoscopy
Colonoscopy
Primary: Adenoma Detection — 63; 59 participants
N/A N=386 Efficacy of Segmental Examination Twice of the Proximal Colon on Adenoma Detection
Colonic Polyps
Primary: Difference of Adenoma Detection Rate in the Proximal Colon Among 2 Group. — 0.236; 0.331 proportion of participants
Phase 2 N=23 Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)
Healthy, no Evidence of Disease · Tobacco Use Disorder
Primary: Baseline in Prostaglandin E2 (PGE2) Within Aberrant Crypt Foci (ACF) — 1.1; 3.4 µg/g protein
Phase 2 N=46 Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
Risk for Colorectal Cancer
Primary: Number of Participants With Anti Muc-1 Antibody — 39 participants